New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
Significant progress related particular to the use of interleukin (IL)-6 and IL17 inhibitors has been made in the pharmacotherapy of rheumatic diseases. IL-6 is a cytokine that has a wide range of biological activity and affects different types of cells. There is evidence for the important role of I...
| Published in: | Современная ревматология |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-10-01
|
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/489 |